objective:to observe the fluorine dara marina (Flud) joint cytarabine (Ara-C), recombinant human granulocyte colony stimulating factor (g-csf) FLAG regimen for refractory/recurrent acute myelogenous leukemia clinical curative effect and adverse reaction. Methods:using fluorine dara marina (Flud) 50 mg/d, intravenous drip, lasts 30 min, d1-d5;Cytarabine (Ara-C) 2 g/d, 4 h after using Flud drip into the, last 3 h d1-d5;Recombinant human granulocyte colony stimulating factor (g-csf) 300 ug/d, hypodermic d0-d5, FLAG was used in treatment of refractory or recurrent acute myelogenous leukemia treatment of 17 cases, the curative effect and adverse reaction was observed. Conclusion:17 cases with complete remission in 11 cases, complete response rate was 64.7%, partial in 3 cases, persist in 1 case, 2 cases died, the effective rate was 82.4%. Main side effects for bone marrow inhibition, infection, gastrointestinal symptoms and mild liver damage. Conclusion:treat/FLAG regimen for recurrent acute myelogenous leukemia is safe and effective.
FLAGAcute myelogenous leukemiaRefractory or recurrent
NETL
NSTL
万方数据
